{"id":2394,"date":"2017-11-07T18:12:35","date_gmt":"2017-11-07T12:42:35","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2394"},"modified":"2021-07-24T12:56:52","modified_gmt":"2021-07-24T07:26:52","slug":"notizia-56","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-56","title":{"rendered":"Teva sells generics; Valeant trades; Roche&#8217;s Genentech; J&#038;J&#8217;s next potential frontier"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d0e088ea2cc\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d0e088ea2cc\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-56\/#Teva_looks_to_sell_generics_in_China_through_joint_venture_with_Guangzhou_Pharma\" >Teva looks to sell generics in China through joint venture with Guangzhou Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-56\/#Valeant_trades_1B_buy_for_6_royalty_on_a_drug_thats_not_selling\" >Valeant trades $1B buy for 6% royalty on a drug that&#8217;s not selling<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-56\/#Roches_Genentech_whacking_130_jobs_at_California_plant\" >Roche&#8217;s Genentech whacking 130 jobs at California plant<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-56\/#J_Js_next_potential_frontier_for_Stelara_can_be_Lupus_thanks_to_positive_phase_2_data\" >J&amp;J&#8217;s next potential frontier for Stelara can be Lupus, thanks to positive phase 2 data<\/a><\/li><\/ul><\/nav><\/div>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Teva_looks_to_sell_generics_in_China_through_joint_venture_with_Guangzhou_Pharma\"><\/span><span style=\"color: #000000;\">Teva looks to sell generics in China through joint venture with Guangzhou Pharma<\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">As the world\u2019s largest generics maker, Teva still doesn\u2019t have much of a presence in China, even though it is a country relies heavily on generics. The Israeli company is looking to remedy that as Teva has said it \u201chas no agreement with any local partner to form a JV in China,\u201d but went short of denying such a possibility or whether it\u2019s in talks with Guangzhou Pharma. Teva had made some inroads in China more than a decade ago with a $7.4 billion Ivax acquisition deal in which it gained 50% of the shares in Kunming Baker Norton Pharma, a joint venture between China\u2019s Kunming Pharma and Ivax. The company\u2019s amoxicillin is one of the best-selling antibiotics in China. But then in 2015, Kunming Pharma bought back 49% of the shares, leaving only 1% for Teva. Teva has an API plant in China\u2014which was dealt a warning letter from the U.S. FDA in April\u2014and is selling drugs through a distribution agreement with a local company.<\/span><\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Valeant_trades_1B_buy_for_6_royalty_on_a_drug_thats_not_selling\"><\/span><span style=\"color: #000000;\">Valeant trades $1B buy for 6% royalty on a drug that&#8217;s not selling<\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">Valeant said it&#8217;s selling Sprout Pharmaceuticals to a group of former Sprout shareholders in exchange for a 6% royalty on <\/span>Addyi<span style=\"color: #000000;\"> sales after 18 months. Valeant says it will lend $25 million to the investors to help them get the Sprout operation up and running. The deal is expected to close by the end of this year. Valeant purchased Sprout for $1 billion in August 2015, with former CEO J. Michael Pearson calling the buy a &#8220;perfect opportunity to establish a new portfolio of important medicines that uniquely impact women.&#8221; As industry watchers know, things for Valeant haven&#8217;t gone according to plan since that deal.<\/span><\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Roches_Genentech_whacking_130_jobs_at_California_plant\"><\/span><span style=\"color: #000000;\">Roche&#8217;s Genentech whacking 130 jobs at California plant<\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">The fortunes of Roche\u2019s Genentech biologics plant in California, to a large degree, have followed the ebb and flow of the Swiss drugmaker\u2019s expected battle with biosimilars of its blockbuster cancer drugs. Right now, biosimilars are on the rise and the California plant\u2019s fortunes are on a downward slide, with dozens of workers set to lose their jobs. Genentech today confirmed 130 workers at the plant in Vacaville will be laid off by the end of the year after determining that fewer workers are needed for the demand it is forecasting for its injected medications. Genentech said that workers will get extended <\/span>healthcare<span style=\"color: #000000;\"> and other help through the transition and that it is \u201ccommitted to the continued success of our operations in Vacaville, which is our largest manufacturing facility and a vital part of the global Roche network.<\/span><\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"J_Js_next_potential_frontier_for_Stelara_can_be_Lupus_thanks_to_positive_phase_2_data\"><\/span><span style=\"color: #000000;\">J&amp;J&#8217;s next potential frontier for Stelara can be Lupus, thanks to positive phase 2 data<\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">Johnson &amp; Johnson has been looking for ways to expand its blockbuster drug Stelara, now that a raft of new competitors <\/span>have<span style=\"color: #000000;\"> made things tougher in psoriasis. And the immunology med might just have a good prospect in lupus. On Nov 6, the New Jersey drugmaker\u2019s Janssen unit said the med had impressed in a phase 2 study. Sixty percent of patients receiving Stelara showed significant improvements in disease activity at week 24 of treatment, while just 31% of the placebo group did. Based on those results, the pharma giant plans to take its star into the next stage of development, Newman Yeilding, Janssen\u2019s head of immunology development, said in a statement, adding that they \u201cprovide a <\/span>strong<span style=\"color: #000000;\"> rationale for moving into a phase 3 clinical development program.\u201d<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Teva looks to sell generics in China through joint venture with Guangzhou Pharma As the world\u2019s largest generics maker, Teva still doesn\u2019t have much of a presence in China, even though it is a country relies heavily on generics. The Israeli company is looking to remedy that as Teva has said it \u201chas no agreement [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2122,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17393,137,163,1135,1130,1129,921,341,1132,1134,1136,524,17591,562,1133,685,1131],"industry":[17225],"therapeutic_areas":[17230,17227],"class_list":["post-2394","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-biosimilars","tag-cancer","tag-china","tag-genentech","tag-generics","tag-guangzhou-pharma","tag-jj","tag-johnson-johnson","tag-kunming-baker-norton-pharma","tag-kunming-pharma","tag-lupus","tag-roche","tag-sprout-pharmaceuticals","tag-teva","tag-u-s-fda","tag-valeant","tag-venture","industry-pharmaceutical","therapeutic_areas-genito-urinary-system-and-sex-hormones","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Teva sells generics; Valeant trades; Roche&#039;s Genentech; J&amp;J&#039;s frontier<\/title>\n<meta name=\"description\" content=\"As the world\u2019s largest generics maker, Teva still doesn\u2019t have much of a presence in China, even though it is a country relies heavily on...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-56\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teva sells generics; Valeant trades; Roche&#039;s Genentech; J&amp;J&#039;s frontier\" \/>\n<meta property=\"og:description\" content=\"As the world\u2019s largest generics maker, Teva still doesn\u2019t have much of a presence in China, even though it is a country relies heavily on...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-56\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-11-07T12:42:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"3000\" \/>\n\t<meta property=\"og:image:height\" content=\"2250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Teva sells generics; Valeant trades; Roche's Genentech; J&J's frontier","description":"As the world\u2019s largest generics maker, Teva still doesn\u2019t have much of a presence in China, even though it is a country relies heavily on...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-56","og_locale":"en_US","og_type":"article","og_title":"Teva sells generics; Valeant trades; Roche's Genentech; J&J's frontier","og_description":"As the world\u2019s largest generics maker, Teva still doesn\u2019t have much of a presence in China, even though it is a country relies heavily on...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-56","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-11-07T12:42:35+00:00","article_modified_time":"2021-07-24T07:26:52+00:00","og_image":[{"width":3000,"height":2250,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-56","url":"https:\/\/www.delveinsight.com\/blog\/notizia-56","name":"Teva sells generics; Valeant trades; Roche's Genentech; J&J's frontier","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-56#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-56#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma.jpg","datePublished":"2017-11-07T12:42:35+00:00","dateModified":"2021-07-24T07:26:52+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"As the world\u2019s largest generics maker, Teva still doesn\u2019t have much of a presence in China, even though it is a country relies heavily on...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-56"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-56#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma.jpg","width":"3000","height":"2250","caption":"Personalized Medicine"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma-300x225.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biosimilars<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">China<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Genentech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">generics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Guangzhou Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">J&amp;J<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Johnson &amp; Johnson<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Kunming Baker Norton Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Kunming Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lupus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sprout Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Teva<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">U.S. FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Valeant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">venture<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biosimilars<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">China<\/span>","<span class=\"advgb-post-tax-term\">Genentech<\/span>","<span class=\"advgb-post-tax-term\">generics<\/span>","<span class=\"advgb-post-tax-term\">Guangzhou Pharma<\/span>","<span class=\"advgb-post-tax-term\">J&amp;J<\/span>","<span class=\"advgb-post-tax-term\">Johnson &amp; Johnson<\/span>","<span class=\"advgb-post-tax-term\">Kunming Baker Norton Pharma<\/span>","<span class=\"advgb-post-tax-term\">Kunming Pharma<\/span>","<span class=\"advgb-post-tax-term\">Lupus<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Sprout Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Teva<\/span>","<span class=\"advgb-post-tax-term\">U.S. FDA<\/span>","<span class=\"advgb-post-tax-term\">Valeant<\/span>","<span class=\"advgb-post-tax-term\">venture<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Nov 7, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Nov 7, 2017 6:12 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2394"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2394\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2122"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2394"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2394"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2394"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2394"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}